Cannabidiol May Treat Inflammatory Lung Diseases, According to New Study
Cannabidiol has a strong anti-inflammatory effect, and can also improve lung function in those with acute lung injury, indicating that it may be a viable treatment option for inflammatory lung diseases, according to a new study published in the journal Immunopharmacology Immunotoxicology.
According to the study; “We have previously shown that the prophylactic treatment with cannabidiol (CBD) reduces inflammation in a model of acute lung injury (ALI). In this work we analyzed the effects of the therapeutic treatment with CBD in mice subjected to the model of lipopolysaccharide (LPS)-induced ALI on pulmonary mechanics and inflammation.”
Researchers administered CBD to mice 6 hours after LPS-induced lung inflamation, and examined the effects 24 hours later. The results showed that “CBD decreased total lung resistance and elastance, leukocyte migration into the lungs, myeloperoxidase activity in the lung tissue, protein concentration and production of pro-inflammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2) in the bronchoalveolar lavage supernatant.
Thus, we conclude that CBD administered therapeutically, i.e. during an ongoing inflammatory process, has a potent anti-inflammatory effect and also improves the lung function in mice submitted to LPS-induced ALI.”
The study concludes; “Therefore the present and previous data suggest that in the future cannabidiol might become a useful therapeutic tool for the attenuation and treatment of inflammatory lung diseases.”
The study was conducted by researchers at the University of São Paulo in Brazil.